Vanda Pharmaceuticals(US:VNDA) ZACKS·2025-05-07 22:10Group 1 - Vanda Pharmaceuticals reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, and compared to a loss of $0.07 per share a year ago, indicating an earnings surprise of 9.09% [1] - The company posted revenues of $50.04 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.47%, and this represents an increase from year-ago revenues of $47.46 million [2] - Vanda has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Group 2 - The stock has underperformed the market, losing about 8.8% since the beginning of the year, compared to the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the coming quarter is -$0.18 on revenues of $55.25 million, and for the current fiscal year, it is -$1.12 on revenues of $225 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8]